Soliton (NSDQ:SOLY) announced today that it entered into a distribution and sales agreement with Aesthetic Solutions. The agreement will see Aesthetic Solutions distribute Soliton’s rapid acoustic pulse (RAP) device and advanced design cartridges during a U.S. commercial launch targeted for the first half of 2021. Get the full story at our sister site, Medical Design & Outsourcing.
Soliton (NSDQ:SOLY) announced that it intends to offer an undisclosed amount of shares of its common stock in an underwritten public offering. The Houston-based medical device company also intends to grant underwriters a 30-day option to purchase up to an additional 15% of the number of shares offered. Cantor Fitzgerald & Co. is acting as the […]
Soliton (NSDQ:SOLY) today said it received special 510(k) premarket notification for its Generation II Rapid Acoustic Pulse device. The Generation II RAP device features the same tattoo-removal technology as the first generation but is modified for improved ease of use in physician offices. “The FDA clearance of our Generation II RAP device marks yet another milestone […]
Soliton (NSDQ:SOLY) said today that it raised $9 million in a private placement for the acoustic tattoo removal aid it’s developing. Houston-based Soliton, which licenses its technology from the University of Texas, is develop a rapid acoustic pulse device that’s designed to make tattoo-removal lasers more effective. The device won 510(k) clearance from the FDA […]